Akkermania Muciniphila: a Rising Star in Tumor Immunology

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Apr 23

PMID 38653927

Authors

Leihan Wang

Dong Tang

Affiliations

Soon will be listed here.

Abstract

Tumor is accompanied by complex and dynamic microenvironment development, and the interaction of all its components influences disease progression and response to treatment. Once the tumor microenvironment has been eradicated, various mechanisms can induce the tumors. Microorganisms can maintain the homeostasis of the tumor microenvironment through immune regulation, thereby inhibiting tumor development. Akkermania muciniphila (A. muciniphila), an anaerobic bacterium, can induce tumor immunity, regulate the gastrointestinal microenvironment through metabolites, outer membrane proteins, and some cytokines, and enhance the curative effect through combined immunization. Therefore, a comprehensive understanding of the complex interaction between A. muciniphila and human immunity will facilitate the development of immunotherapeutic strategies in the future and enable patients to obtain a more stable clinical response. This article reviews the most recent developments in the tumor immunity of A. muciniphila.

Citing Articles

: new insights into resistance to gastrointestinal stress, adhesion, and protein interaction with human mucins through optimised trials and bioinformatics tools.

Vergalito F, Bagnoli D, Maiuro L, Pannella G, Palombo V, Testa B Front Microbiol. 2024; 15:1462220.

PMID: 39564479 PMC: 11573778. DOI: 10.3389/fmicb.2024.1462220.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Kuo C, Chou H, Chiu Y, Cheng A, Fan C, Chang Y . Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett. 2020; 474:138-150. DOI: 10.1016/j.canlet.2020.01.019. View

Weng Y, Tseng H, Chen Y, Shen P, Haq A, Chen L . MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019; 18(1):42. PMC: 6421700. DOI: 10.1186/s12943-019-0988-0. View

Wang J, Sun J, Liu L, Flies D, Nie X, Toki M . Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019; 25(4):656-666. PMC: 7175920. DOI: 10.1038/s41591-019-0374-x. View

Wong T, Ng K, Tan K, Chan L, Zhou L, Che N . CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. Hepatology. 2019; 71(4):1279-1296. DOI: 10.1002/hep.30923. View

Boulch M, Grandjean C, Cazaux M, Bousso P . Tumor Immunosurveillance and Immunotherapies: A Fresh Look from Intravital Imaging. Trends Immunol. 2019; 40(11):1022-1034. DOI: 10.1016/j.it.2019.09.002. View

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B . Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019; 18(1):10. PMC: 6332843. DOI: 10.1186/s12943-018-0928-4. View

Tang S, Qin C, Hu H, Liu T, He Y, Guo H . Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells. 2022; 11(3). PMC: 8834198. DOI: 10.3390/cells11030320. View

Bagchi S, Yuan R, Engleman E . Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2020; 16:223-249. DOI: 10.1146/annurev-pathol-042020-042741. View

10.

Jogalekar M, Rajendran R, Khan F, Dmello C, Gangadaran P, Ahn B . CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022; 13:925985. PMC: 9355792. DOI: 10.3389/fimmu.2022.925985. View

11.

Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O . Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma. J Clin Invest. 2023; 133(6). PMC: 10014104. DOI: 10.1172/JCI164809. View

12.

Zettl M, Wurm M, Schaaf O, Mostbock S, Tirapu I, Apfler I . Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. Oncoimmunology. 2022; 11(1):2080328. PMC: 9225207. DOI: 10.1080/2162402X.2022.2080328. View

13.

Davar D, Dzutsev A, McCulloch J, Rodrigues R, Chauvin J, Morrison R . Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021; 371(6529):595-602. PMC: 8097968. DOI: 10.1126/science.abf3363. View

14.

Routy B, Le Chatelier E, Derosa L, Duong C, Alou M, Daillere R . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017; 359(6371):91-97. DOI: 10.1126/science.aan3706. View

15.

Kobyliak N, Falalyeyeva T, Kyriachenko Y, Tseyslyer Y, Kovalchuk O, Hadiliia O . Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. Minerva Endocrinol (Torino). 2022; 47(2):242-252. DOI: 10.23736/S2724-6507.22.03752-6. View

16.

Kim J, Kang S, Lee J, Park S, Lee J . The evolution and competitive strategies of in gut. Gut Microbes. 2022; 14(1):2025017. PMC: 8920140. DOI: 10.1080/19490976.2021.2025017. View

17.

Zhang T, Li Q, Cheng L, Buch H, Zhang F . Akkermansia muciniphila is a promising probiotic. Microb Biotechnol. 2019; 12(6):1109-1125. PMC: 6801136. DOI: 10.1111/1751-7915.13410. View

18.

Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L . A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2016; 23(1):107-113. DOI: 10.1038/nm.4236. View

19.

Zhao Q, Yu J, Hao Y, Zhou H, Hu Y, Zhang C . plays critical roles in host health. Crit Rev Microbiol. 2022; 49(1):82-100. DOI: 10.1080/1040841X.2022.2037506. View

20.

Pietrzak B, Tomela K, Olejnik-Schmidt A, Mackiewicz A, Schmidt M . Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells. Int J Mol Sci. 2020; 21(23). PMC: 7731431. DOI: 10.3390/ijms21239254. View